Gillian Langford

Gillian has over 25 years research and development experience in both pharmaceutical and biotechnology companies.

Gillian joined Artios from Bicycle Therapeutics where she was part of the Leadership team and was VP of Clinical and Project Management and responsible for moving Bicycle’s lead compound into the clinic. Prior to joining Bicycle Gillian was Director of Programme Management at Boyd Consultants and worked with European and North American companies developing oncology products and gene based medicines.

Gillian also worked at Alizyme Therapeutics, Ark Therapeutics and Imutran Ltd, a Novartis Pharma AG company. At Ark Therapeutics Gillian was responsible for all aspects of the company’s lead gene therapy product, including non-clinical studies, manufacturing, regulatory and clinical trials (Phases 2 and 3).

At Imutran Gillian worked in the field of xenotransplantation, initially as Unit Head of Molecular Biology and subsequently as Unit Head of Retroviral research. Gillian was responsible for internal research projects and collaborations with academic groups.

Gillian graduated from Imperial College London and obtained her Ph.D. in molecular biology at York University.